230 related articles for article (PubMed ID: 24611018)
21. Gefitinib or erlotinib in previously treated non-small-cell lung cancer patients: a cohort study in Taiwan.
Chang CH; Lee CH; Ko JC; Chang LY; Lee MC; Wang JY; Yu CJ
Cancer Med; 2017 Jul; 6(7):1563-1572. PubMed ID: 28639751
[TBL] [Abstract][Full Text] [Related]
22. Neoadjuvant and adjuvant epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) therapy for lung cancer.
Zhai H; Zhong W; Yang X; Wu YL
Transl Lung Cancer Res; 2015 Feb; 4(1):82-93. PubMed ID: 25806348
[TBL] [Abstract][Full Text] [Related]
23. Lifestyle risks exposure and response predictor of gefitinib in patients with non-small cell lung cancer.
Ying H; Yang XD; Sun Z; Ning X; Wang Y; Bai C; Chen S; Wang Y
Med Oncol; 2014 Oct; 31(10):220. PubMed ID: 25216867
[TBL] [Abstract][Full Text] [Related]
24. Clinical utility of erlotinib for the treatment of non-small-cell lung cancer in Japanese patients: current evidence.
Togashi Y; Hayashi H; Nakagawa K; Nishio K
Drug Des Devel Ther; 2014; 8():1037-46. PubMed ID: 25114510
[TBL] [Abstract][Full Text] [Related]
25. Epidermal growth factor receptor tyrosine kinase inhibitors as initial therapy for non-small cell lung cancer: focus on epidermal growth factor receptor mutation testing and mutation-positive patients.
Roengvoraphoj M; Tsongalis GJ; Dragnev KH; Rigas JR
Cancer Treat Rev; 2013 Dec; 39(8):839-50. PubMed ID: 23768755
[TBL] [Abstract][Full Text] [Related]
26. First-line treatment with irreversible tyrosine kinase inhibitors associated with longer OS in EGFR mutation-positive non-small cell lung cancer.
Su PL; Chen CW; Wu YL; Lin CC; Su WC
Thorac Cancer; 2021 Feb; 12(3):287-296. PubMed ID: 33336895
[TBL] [Abstract][Full Text] [Related]
27. Mediating EGFR-TKI Resistance by VEGF/VEGFR Autocrine Pathway in Non-Small Cell Lung Cancer.
Osude C; Lin L; Patel M; Eckburg A; Berei J; Kuckovic A; Dube N; Rastogi A; Gautam S; Smith TJ; Sreenivassappa SB; Puri N
Cells; 2022 May; 11(10):. PubMed ID: 35626731
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and safety of maintenance erlotinib in Asian patients with advanced non-small-cell lung cancer: a subanalysis of the phase III, randomized SATURN study.
Wu YL; Kim JH; Park K; Zaatar A; Klingelschmitt G; Ng C
Lung Cancer; 2012 Aug; 77(2):339-45. PubMed ID: 22494567
[TBL] [Abstract][Full Text] [Related]
29. Comparison of clinical outcomes of osimertinib and first-generation EGFR-tyrosine kinase inhibitors (TKIs) in TKI-untreated EGFR-mutated non-small-cell lung cancer with leptomeningeal metastases.
Tamura K; Yoshida T; Masuda K; Matsumoto Y; Shinno Y; Okuma Y; Goto Y; Horinouchi H; Yamamoto N; Ohe Y
ESMO Open; 2023 Aug; 8(4):101594. PubMed ID: 37517364
[TBL] [Abstract][Full Text] [Related]
30. Risk of Treatment-Related Toxicities from EGFR Tyrosine Kinase Inhibitors: A Meta-analysis of Clinical Trials of Gefitinib, Erlotinib, and Afatinib in Advanced EGFR-Mutated Non-Small Cell Lung Cancer.
Ding PN; Lord SJ; Gebski V; Links M; Bray V; Gralla RJ; Yang JC; Lee CK
J Thorac Oncol; 2017 Apr; 12(4):633-643. PubMed ID: 28007626
[TBL] [Abstract][Full Text] [Related]
31. Heterogeneous resistance mechanisms in an EGFR exon 19-mutated non-small cell lung cancer patient treated with erlotinib: Persistent FGFR3-mutation, localized transformation to EGFR-mutated SCLC, and acquired T790M EGFR-mutation.
Santoni-Rugiu E; Grauslund M; Melchior LC; Costa JC; Sørensen JB; Urbanska EM
Lung Cancer; 2017 Nov; 113():14-17. PubMed ID: 29110841
[TBL] [Abstract][Full Text] [Related]
32. Aumolertinib: A Review in Non-Small Cell Lung Cancer.
Shirley M; Keam SJ
Drugs; 2022 Apr; 82(5):577-584. PubMed ID: 35305259
[TBL] [Abstract][Full Text] [Related]
33. "Who should receive epidermal growth factor receptor inhibitors for non-small cell lung cancer and when?".
Hann CL; Brahmer JR
Curr Treat Options Oncol; 2007 Feb; 8(1):28-37. PubMed ID: 17634830
[TBL] [Abstract][Full Text] [Related]
34. Update of epidermal growth factor receptor-tyrosine kinase inhibitors in non-small-cell lung cancer.
Chen YM
J Chin Med Assoc; 2013 May; 76(5):249-57. PubMed ID: 23683257
[TBL] [Abstract][Full Text] [Related]
35. β-Elemene enhances erlotinib sensitivity through induction of ferroptosis by upregulating lncRNA H19 in EGFR-mutant non-small cell lung cancer.
Xu C; Jiang ZB; Shao L; Zhao ZM; Fan XX; Sui X; Yu LL; Wang XR; Zhang RN; Wang WJ; Xie YJ; Zhang YZ; Nie XW; Xie C; Huang JM; Wang J; Wang J; Leung EL; Wu QB
Pharmacol Res; 2023 May; 191():106739. PubMed ID: 36948327
[TBL] [Abstract][Full Text] [Related]
36. Experience with erlotinib in the treatment of non-small cell lung cancer.
Landi L; Cappuzzo F
Ther Adv Respir Dis; 2015 Aug; 9(4):146-63. PubMed ID: 26063687
[TBL] [Abstract][Full Text] [Related]
37. Difference in central nerve system metastasis during gefitinib or erlotinib therapy in patients with
Yoshida K; Kanda S; Shiraishi H; Goto K; Itahashi K; Goto Y; Horinouchi H; Fujiwara Y; Nokihara H; Yamamoto N; Ohe Y
J Thorac Dis; 2019 Apr; 11(4):1347-1354. PubMed ID: 31179076
[TBL] [Abstract][Full Text] [Related]
38. Epidermal growth factor receptor tyrosine kinase inhibitors vs conventional chemotherapy in non-small cell lung cancer harboring wild-type epidermal growth factor receptor: a meta-analysis.
Lee JK; Hahn S; Kim DW; Suh KJ; Keam B; Kim TM; Lee SH; Heo DS
JAMA; 2014 Apr; 311(14):1430-7. PubMed ID: 24715074
[TBL] [Abstract][Full Text] [Related]
39. Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802).
Zhou C; Wu YL; Chen G; Feng J; Liu XQ; Wang C; Zhang S; Wang J; Zhou S; Ren S; Lu S; Zhang L; Hu C; Hu C; Luo Y; Chen L; Ye M; Huang J; Zhi X; Zhang Y; Xiu Q; Ma J; Zhang L; You C
Ann Oncol; 2015 Sep; 26(9):1877-1883. PubMed ID: 26141208
[TBL] [Abstract][Full Text] [Related]
40. Evidence for disease control with erlotinib after gefitinib failure in typical gefitinib-sensitive Asian patients with non-small cell lung cancer.
Wong AS; Soong R; Seah SB; Lim SW; Chuah KL; Nga ME; Chin TM; Soo RA
J Thorac Oncol; 2008 Apr; 3(4):400-4. PubMed ID: 18379359
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
